RECRUITING

Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.

Official Title

Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial

Quick Facts

Study Start:2023-12-13
Study Completion:2027-01-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06647459

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Adults aged 18 and older
  2. 2. Diagnosed with AF before age 60
  3. 3. Scheduled for catheter-based AF ablation (de-novo or repeat)
  4. 4. Able to provide written, informed consent
  5. 5. P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.
  1. 1. Diagnosed with a genetic CM or arrhythmia syndrome prior to AF
  2. 2. VUS in 'possibly pathogenic' subgroup (control group only)
  3. 3. Pacemaker or ICD
  4. 4. Previous PVC or VT ablation
  5. 5. LVEF \<20%
  6. 6. Prosthetic mitral or aortic valve
  7. 7. Contraindication to heparin
  8. 8. Prior myocardial infarction.

Contacts and Locations

Study Contact

Dakota D Grauherr, RN
CONTACT
615-714-8674
dakota.grauherr@vumc.org
Diane M Crawford, RN
CONTACT
615-981-2054
diane.m.crawford@vumc.org

Principal Investigator

Moore B Shoemaker, MD
PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center

Study Locations (Sites)

Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States

Collaborators and Investigators

Sponsor: Vanderbilt University Medical Center

  • Moore B Shoemaker, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-13
Study Completion Date2027-01-01

Study Record Updates

Study Start Date2023-12-13
Study Completion Date2027-01-01

Terms related to this study

Keywords Provided by Researchers

  • catheter ablation
  • genomics

Additional Relevant MeSH Terms

  • Ventricular Tachycardia
  • Atrial Fibrillation